Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články
PubMed
30773756
DOI
10.1111/pedi.12833
Knihovny.cz E-zdroje
- Klíčová slova
- children, diabetes technology, reimbursement, type 1 diabetes,
- MeSH
- diabetes mellitus 1. typu krev farmakoterapie ekonomika epidemiologie MeSH
- dítě MeSH
- dospělí MeSH
- hypoglykemika aplikace a dávkování ekonomika MeSH
- inzulin aplikace a dávkování ekonomika MeSH
- inzulinové infuzní systémy ekonomika MeSH
- kojenec MeSH
- krevní glukóza analýza MeSH
- lidé MeSH
- longitudinální studie MeSH
- mladiství MeSH
- mladý dospělý MeSH
- náklady a analýza nákladů MeSH
- novorozenec MeSH
- osobní újma zaviněná nemocí MeSH
- předškolní dítě MeSH
- selfmonitoring glykemie ekonomika přístrojové vybavení MeSH
- úhrada zdravotního pojištění * ekonomika statistika a číselné údaje trendy MeSH
- vynálezy ekonomika statistika a číselné údaje trendy MeSH
- zdravotnické prostředky ekonomika MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Názvy látek
- hypoglykemika MeSH
- inzulin MeSH
- krevní glukóza MeSH
BACKGROUND: Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. METHODS: The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. RESULTS: We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. CONCLUSIONS: Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.
APDP Diabetes Portugal and Nova Medical School Lisbon Portugal
Department of Medical Psychology Hannover Medical School Hannover Germany
Department of Pediatrics Diabetes Center P and A Kyriakou Children's Hospital Athens Greece
Department of Pediatrics KLE University's Jawaharlal Nehru Medical College Belgaum Belgaum India
Department of Pediatrics Medical University of Warsaw Warsaw Poland
Department of Pediatrics Medical University Varna UMHAT Sv Marina Varna Bulgaria
Department of Pediatrics Motol University Hospital Prague Czech Republic
Citace poskytuje Crossref.org
